Skip to main content

MoneyWorks4Me

Zydus Lifesciences informs about press release

06 Oct 2022 Evaluate

Zydus Lifesciences has informed that it enclosed a copy of press release dated October 6, 2022, titled ‘Zydus receives final approval from USFDA and 180 days shared exclusivity for Brivaracetam Tablets’.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1896.00
Dr. Reddys Labs. 1376.00
Cipla 1417.00
Lupin 2021.00
Zydus Lifesciences 1190.10
View more..